University of CalgaryCalgary, AB, Canada
72 - Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
Wednesday, October 30, 20249:40 AM – 9:50 AM ET